as 10-17-2024 4:00pm EST
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | BOSTON |
Market Cap: | 716.9M | IPO Year: | 2010 |
Target Price: | $12.00 | AVG Volume (30 days): | 1.5M |
Analyst Decision: | Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | 0.06 | EPS Growth: | N/A |
52 Week Low/High: | $3.79 - $15.70 | Next Earning Date: | 11-07-2024 |
Revenue: | $400,565,000 | Revenue Growth: | -6.25% |
Revenue Growth (this year): | -17.94% | Revenue Growth (next year): | 2.80% |
Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
---|---|---|---|---|---|---|---|---|---|
John Minardo | IRWD | Chief Legal Officer | Aug 12 '24 | Sell | $4.27 | 9,910 | $42,315.70 | 284,661 | |
Silver Ronald | IRWD | Principal Accounting Officer | Aug 12 '24 | Sell | $4.27 | 3,107 | $13,266.89 | 158,370 |
IRWD Breaking Stock News: Dive into IRWD Ticker-Specific Updates for Smart Investing
GuruFocus.com
a day ago
Insider Monkey
2 days ago
GuruFocus.com
8 days ago
Argus Research
9 days ago
Zacks
a month ago
MT Newswires
a month ago
Insider Monkey
2 months ago
Business Wire
2 months ago
The information presented on this page, "IRWD Ironwood Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.